Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100006
Funder
Australian Research Council
Funding Amount
$600,000.00
Summary
An adaptable and dedicated linear accelerator for medical radiation research. Leading radiation scientists developing innovative methods and devices for treating cancer patients will collaborate in future research using this highly adaptable linear accelerator for medical radiation research. Innovations in tumour targeting, better patient safety, new medical devices and improved cancer outcomes are expected.
Targeting 124I To The DNA Of Tumours For PET Imaging And Auger-Radiotherapy
Funder
National Health and Medical Research Council
Funding Amount
$787,000.00
Summary
The aim of this project is to develop a new method of targeting radioactivity to tumours, for detection and treatment, using a radioactive element (iodine-124). Iodine-124 emits a form of radiation called positrons, detected by a new imaging technique - Positron Emission Tomography (PET). Therefore, tumours labelled with iodine-124 can be imaged by PET. Also, iodine-124 is amongst a class of radioactive atoms (called Auger-emitters) that emit a shower of very low energy electrons. This intense f ....The aim of this project is to develop a new method of targeting radioactivity to tumours, for detection and treatment, using a radioactive element (iodine-124). Iodine-124 emits a form of radiation called positrons, detected by a new imaging technique - Positron Emission Tomography (PET). Therefore, tumours labelled with iodine-124 can be imaged by PET. Also, iodine-124 is amongst a class of radioactive atoms (called Auger-emitters) that emit a shower of very low energy electrons. This intense focus of radiation damage, can be exploited to kill cancer cells by inflicting lethal DNA damage. To bring the iodine-124 close to the DNA molecule, we will attach it to a DNA-binding drug linked to a tumour-seeking protein, such as an anti-tumour antibody. After injection of the radioactive drug-protein cocktail, PET imaging will be used to assess the extent of tumour targeting, to enable calculation of the amount of cocktail required for successful tumour treatment by further injections. There are some situations where tumour imaging needs to be non-damaging, such as in using PET imaging to assess the success of surgical removal of a tumour. Therefore, we will design an alternative version of the iodine-124-labelled DNA- binding drug with the radioactive atom in a location that will minimise DNA damage from radioactive decay. In this imaging-only scenario, the Auger-emission feature is suppressed whilst still exploiting positron-emission for imaging. The stability of radioactive atoms varies widely, and the half-life of iodine-124 (about four days) is an ideal compromise for imaging and treatment. By contrast, the utility of the most commonly used isotope for PET imaging, fluorine-18, is limited by its half-life of only a few hours. The PET Centre at PeterMac will soon produce iodine-124, joining one of only a few centres throughout the world. Peter Mac has recently lodged a patent application for the technology to be developed in this project.Read moreRead less
Examining The Role Of HIF-1a And Snail-2 In Radiosensitivity Of Oropharyngeal Squamous Cell Carcinoma
Funder
National Health and Medical Research Council
Funding Amount
$78,492.00
Summary
Human papillomavirus (HPV)-induced oropharyngeal squamous cell carcinoma has a significantly better prognosis than that caused by tobacco and/or alcohol. The favorable prognosis is due to a better response to treatment with radiation therapy and chemotherapy but the exact mechanisms are still not clear. This project will investigate these mechanisims at the molecular level and ultimately it will lead us to the development of strategies to improve the response of both HPV and non-HPV induced orop ....Human papillomavirus (HPV)-induced oropharyngeal squamous cell carcinoma has a significantly better prognosis than that caused by tobacco and/or alcohol. The favorable prognosis is due to a better response to treatment with radiation therapy and chemotherapy but the exact mechanisms are still not clear. This project will investigate these mechanisims at the molecular level and ultimately it will lead us to the development of strategies to improve the response of both HPV and non-HPV induced oropharyngeal cancer to radiation therapy.Read moreRead less
A Randomized Trial Of 2 Radiation And Systemic Therapy Strategies In Good Prognosis Advanced Human Papilloma Virus -associated Cancer Of The Tonsil And Base Of Tongue
Funder
National Health and Medical Research Council
Funding Amount
$1,097,932.00
Summary
Cancers of the tonsil and base of tongue due to the human papilloma virus have a better prognosis than other head and neck cancers, but standard treatment can result in significant acute and late side effects. This trial aims to compare two types of chemotherapy and radiotherapy that are less intensive than standard treatment. The aim of the trial is to determine which treatment is associated with better quality of life and less side effects, while maintaining efficacy.
First Ever System To Continuously And Directly Measure The Internal Anatomy To Guide Breast Cancer Radiation Treatment Under Deep Inspiration Breath Hold
Funder
National Health and Medical Research Council
Funding Amount
$409,766.00
Summary
We propose a first ever system to continuously and directly measure the internal anatomy of the patient during radiotherapy of left sided breast cancer to ensure correct position of patient and radiation beam. The proposed method involves no additional radiation dose to the patient. It relies on existing components of modern radiation treatment machines, requiring no additional equipment, which will make it easy to implement widely.
A Prospective Clinical Trial To Establish The Significance Of Interim FDG And FLT PET/CT Scans As Biomarkers Of Patient Prognosis And Individualised Radiation Therapy In Non-small Cell Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$532,902.00
Summary
Positron Emission Tomography (PET)/Computed Tomography (CT) scanners pinpoint the location of cancer cells in people prior to and after treatment. This innovative study will use during treatment PET/CT scans to establish the response of lung tumours to radiation therapy (RT). We will use these scans to simulate the delivery of highly targeted, individualised RT and to predict patient prognosis, with the ultimate aim of increasing survival and minimising side effects in patients with lung cancer
Overcoming Radiation Resistance In Glioblastoma With Novel Metabolic Modulations
Funder
National Health and Medical Research Council
Funding Amount
$62,554.00
Summary
Aim 1 is to document the pathological, surgical, radiotherapy and chemotherapy patterns of care in the Australian setting using the AGOG (Australian Genomics and Clinical Outcomes of Glioma) database. The second aim to develop non-invasive imaging biomarkers which can be used to monitor treatment efficacy. The third aim is to improve outcomes using drug and radiation combination therapy. in the treatment of high grade gliomas.
Improving Radiation Therapy Of Static And Moving Targets Using High Spatial Resolution Real-time Dosimeters
Funder
National Health and Medical Research Council
Funding Amount
$544,425.00
Summary
Radiation therapy is a major oncology modality for cancer treatment and more than 50% of cancer patients can benefit from radiotherapy at some stage of management. This project will develop two real-time, high spatial resolution dosimetry systems for quality assurance of contemporary radiation treatments of static and movable targets. It will be possible to minimize human and robotic system error so as to guarantee accurate cancer treatment delivery and improve the clinical outcomes of radiother ....Radiation therapy is a major oncology modality for cancer treatment and more than 50% of cancer patients can benefit from radiotherapy at some stage of management. This project will develop two real-time, high spatial resolution dosimetry systems for quality assurance of contemporary radiation treatments of static and movable targets. It will be possible to minimize human and robotic system error so as to guarantee accurate cancer treatment delivery and improve the clinical outcomes of radiotherapy.Read moreRead less
A Randomised Trial Of Surgery Versus Surgery Plus Radiotherapy For Regional Control In Patients With Stage 3 Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$305,163.00
Summary
Melanoma is a common disease in Australia. When it has spread to lymph glands it has a poor prognosis. If not controlled it can lead to severe local symptoms including pain, bleeding and disabilty. This is a world first clinical trial involving radiotherapy given after surgery for melanoma involving regional lymph glands. It involves a head to head comparison of surgery alone versus surgery followed by radiotherapy. The target is 230 patients, more than 160 being so far recruited. The main outco ....Melanoma is a common disease in Australia. When it has spread to lymph glands it has a poor prognosis. If not controlled it can lead to severe local symptoms including pain, bleeding and disabilty. This is a world first clinical trial involving radiotherapy given after surgery for melanoma involving regional lymph glands. It involves a head to head comparison of surgery alone versus surgery followed by radiotherapy. The target is 230 patients, more than 160 being so far recruited. The main outcome of the study is control of melanoma in the lymph gland basin. Other outcomes are survival, time to recurrence, side-effects (such as lymphoedema) and quality of life. The trial currently involves 13 centres in Australia, New Zealand and the Netherlands. It is expects to be completed in 2007.Read moreRead less
Reducing The Greatest Uncertainty In Radiotherapy.
Funder
National Health and Medical Research Council
Funding Amount
$594,197.00
Summary
The weakest link in radiotherapy is defining treatment volumes (contouring). Lack of accuracy and consistency in clinical trial contouring has been shown to result in reduced patient outcomes. Manual review of contouring is resource intensive, expensive and for advanced treatments unachievable in a timely fashion. We will assess an automated approach to contouring assessment using 4 clinical trial datasets, changing practice for future studies and enabling consistent assessment in the clinic.